Comatose Within 6 Weeks, but Still Alive After 3 Years, Creutzfeldt‐Jakob Disease With Unusual Progression by Christopher, Julia Kathleen et al.
School of Medicine Faculty Publications School of Medicine 
4-19-2020 
Comatose Within 6 Weeks, but Still Alive After 3 Years, 
Creutzfeldt‐Jakob Disease With Unusual Progression 
Julia Kathleen Christopher 
University of Nevada, Las Vegas, julia.christopher@unlv.edu 
Brian Khong 
Adventist Health White Memorial 
Amin Abolfazli 
Ross School of Medicine 
Antonio Liu 
Adventist Health White Memorial, liuak@ah.org 
Follow this and additional works at: https://digitalscholarship.unlv.edu/som_fac_articles 
 Part of the Immunology and Infectious Disease Commons, and the Neuroscience and Neurobiology 
Commons 
Repository Citation 
Christopher, J. K., Khong, B., Abolfazli, A., Liu, A. (2020). Comatose Within 6 Weeks, but Still Alive After 3 
Years, Creutzfeldt‐Jakob Disease With Unusual Progression. Clinical Case Reports 1-5. 
http://dx.doi.org/10.1002/ccr3.2807 
This Article is protected by copyright and/or related rights. It has been brought to you by Digital Scholarship@UNLV 
with permission from the rights-holder(s). You are free to use this Article in any way that is permitted by the 
copyright and related rights legislation that applies to your use. For other uses you need to obtain permission from 
the rights-holder(s) directly, unless additional rights are indicated by a Creative Commons license in the record and/
or on the work itself. 
 
This Article has been accepted for inclusion in School of Medicine Faculty Publications by an authorized 
administrator of Digital Scholarship@UNLV. For more information, please contact digitalscholarship@unlv.edu. 
Clin Case Rep. 2020;00:1–5.    | 1wileyonlinelibrary.com/journal/ccr3
1 |  INTRODUCTION
Creutzfeldt-Jakob disease, while rare, is the most common 
human prion disease (proteinaceous and infectious) which 
results in rapidly progressive dementia. It remains incur-
able with mortality typically within 12 months of diagnosis. 
Patients with CJD have a mutated form of PrP (PrPSc). PrPC 
is a normal, cell surface glycoprotein formed in the brain and 
guts with unknown normal function. PrPSc is synthesized in 
large quantities results in exponential misfolding and neuro-
degeneration. The proposed mechanism suggests the alpha 
helical regions of PrPC bind to the beta pleated sheets of PrPSc 
and continue to propagate, similar to Alzheimer's disease and 
Parkinson's disease. Etiology for the mutated protein varies 
based on CJD type.1,2
Creutzfeldt-Jakob disease is the cause of 1/6000-1/10 000 
death per year in United States.
Three types of CJD exist1,2:
1. Sporadic CJD (sCJD) (85%-90%). It occurs without any 
identifiable pattern and appears to be a spontaneous muta-
tion of PrP. Worldwide incidence is 1-1.5 per 1 000 000 
annually. The average age at death is 68  years old.
2. Genetic or familial CJD (5%-15%). Two distinct forms 
are Gerstmann-Straussler-Scheinker syndrome and fatal 
familial insomnia. Both are more typical, rapidly progres-
sive forms of the disease.
3. Infectious CJD includes dietary and iatrogenic (<1%). 
Dietary include two types: kuru and variant CJD. Kuru was 
found exclusively in a New Guinea tribe with supposed 
transmission via ritualistic cannibalistic practice.2 Variant 
CJD (vCJD), also known as “Mad Cow Disease,” was dis-
covered in more than 200 people in Great Britain in 1994 
who had eaten beef contaminated with the prion disease 
bovine spongiform encephalopathy. The disease manifested 
10 years after an outbreak was observed in cattle.2 Moreover, 
iatrogenic cases of CJD have been recognized in patients 
Received: 16 December 2019 | Revised: 3 February 2020 | Accepted: 6 February 2020
DOI: 10.1002/ccr3.2807  
C A S E  R E P O R T
Comatose within 6 weeks, but still alive after 3 years, Creutzfeldt-
Jakob disease with unusual progression
Julia Kathleen Christopher1 |   Brian Khong2  |   Amin Abolfazli3  |   Antonio Liu4
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original 
work is properly cited.
© 2020 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd
Patient was seen and most of the work done for this paper at: Adventist Health White Memorial, 1720 Cesar Chavez Ave, Los Angeles, CA 90033. 
1Department of Pulmonary and Critical 
Care Medicine, UNLV, Las Vegas, Nevada
2Internal Medicine, Adventist Health White 
Memorial, Los Angeles, California
3Ross School of Medicine, North 
Brunswick, New Jersey
4Neurology, Adventist Health White 
Memorial, Los Angeles, California
Correspondence
Antonio Liu, Loma Linda University 
School of Medicine, Loma Linda, CA and 
Adventist Health White Memorial, 1720 
East Cesar E. Chavez Ave., Los Angeles, 
CA 90033.
Email: liuak@ah.org
Abstract
Creutzfeldt-Jakob disease (CJD) should still be considered in a patient presenting 
with rapidly progressive dementia and negative CSF 14-3-3 protein and RT-QulC. 
Treatable causes of encephalopathy must be ruled out. Neurodegenerative diseases 
must also be considered.
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who underwent cadaveric dura grafts, human growth hor-
mone injections, corneal transplants, and procedures using 
contaminated neurosurgical instruments.1
Creutzfeldt-Jakob disease may present with a prodrome of 
decreased concentration, memory loss, depression, and anxi-
ety. As the disease progresses, affected patients may develop 
myoclonus, extrapyramidal symptoms, akinetic mutism, vi-
sual impairments, hypersomnia, psychiatric manifestation, 
and cerebellar disturbances. These patients progressively 
decline cognitively and functionally eventually becoming co-
matose then dying. Definitive diagnosis is by neuropatholog-
ical, immunocytochemically, Western blot confirmed PrPSc 
or presence of scrapie-associated fibrils. Probable diagnosis, 
after ruling out other etiologies, is by neuropsychiatric dis-
order, plus RT-QulC analysis (99%-100% specific) OR at 
least two of myoclonus, visual or cerebellar signs, pyramidal/
extrapyramidal signs, akinetic mutism AND at least one of 
typical EEG, positive CSF 14-3-3 protein, or positive MRI.1 
To date, there is no effective treatment; disease is uniformly 
fatal.
2 |  CASE REPORT
A 53-year-old male was brought to our Emergency 
Department with 1 month of confusion. He was completely 
normal 1 month prior, running a successful small business. 
The patient's wife initially observed confusion which wors-
ened with impaired functioning, impairing his ability to work 
and care for his children. The patient was initially brought to 
an outside facility around 2 weeks into this illness. At that 
time, his symptoms had progressed to difficulty recogniz-
ing family, mutism, and hypersomnia. He then developed 
myoclonus with agitation and combativeness. MRI and CSF 
analysis from the outside facility were unremarkable (includ-
ing an initially unavailable report of “unlikely prion disease” 
with no 14-3-3 protein detected). The patient was released 
with eventual admission to our hospital. By week 4 of his 
disease, he became bedridden, disoriented, and unable to 
recognize family. He developed myoclonic jerks and did not 
follow commands. Moreover, he had moderately increased 
muscle tone and incontinence. He never developed psychi-
atric manifestations. His clinical course continued to decline 
with subsequent intubation for airway protection by week 5 
with deterioration by week 6 to GCS of 1/1/1. He has re-
mained in this state ever since.
Past medical history was significant for remote history of 
nasal carcinoma. The patient took no home medications. His 
surgical history was significant for nasal carcinoma resec-
tion. Family history consisted of a father with hypertension. 
The patient denied using tobacco or drugs and used alcohol 
socially only. He ran a busy automobile mechanic business. 
He traveled to El Salvador 1 year prior to presentation. There 
are no recent sick or animal contacts.
At our hospital, he was never febrile with stable vital 
signs. After his initial negative MRI at the outside facility, 
MRI head began to show bilateral caudate and basal ganglia 
abnormality on T2 as well as DWI. Additionally, there is a 
cortical ribbon involvement in the posterior portion of both 
hemispheres (Figure  1A,B). There was never any pulvinar 
F I G U R E  1  A, MRI abnormal signal density on bilateral caudate 
and basal ganglia on DWI. B, MRI abnormal signal density on bilateral 
caudate and basal ganglia on T2
(A)
(B)
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involvement. Routine complete blood count, complete met-
abolic panel, and coagulation studies were within normal 
limits. Serum analysis showed normal levels of vitamin B12, 
folate, methyl malonic acid, C-reactive protein, erythrocyte 
sedimentation rate, Cryptococcus antigen screen, Treponema 
antibody EIA, and ceruloplasmin. N-methyl D-aspartate 
(NMDA) receptor antibodies and antineuronal antibody panel 
were negative. HIV was non-reactive. EEGs showed periodic 
synchronized electric discharges which were refractory to 
antiepileptic drugs (Figure 2). Repeat lumbar puncture was 
performed and showed WBC 86/mm3 with 38% neutrophils, 
34% lymphocytes, and 8% bands, RBC 3048 mm3, glucose 
level of 104 mg/dL, and protein level 100 mg/dL. CSF herpes 
simplex virus PCR, VDRL syphilis screen, West Nile IgM 
and IgG ELISA, and AFB stain were all negative. Cytology 
showed inflammatory cells but no malignant cells. Repeat 
CSF 14-3-3 protein and RT-QuIC collected at 4 week after 
initial symptoms finally came back positive with probabil-
ity of prion disease >98%. Brain biopsy, although requested, 
never took place.
After 2  months of acute hospitalization but continued 
stability, patient was placed at a nearby subacute facility. 
Follow-up visits show no change nor deterioration. Patient 
remains on mechanical ventilation via tracheostomy and tube 
feeding at 3 year point from original symptoms.
3 |  DISCUSSION
Although CJD is a rare disease, it should be considered 
when a patient is presenting with a rapidly progressive 
dementia. Treatable causes of encephalopathy such as 
meningitis, meningoencephalitis, CNS vasculitis, hypo-
thyroidism, sarcoidosis, toxicities, paraneoplastic syn-
dromes, and primary neoplasms must be ruled out.2,3 
Neurodegenerative diseases such as Alzheimer's disease, 
dementia with Lewy bodies,2-5 frontotemporal dementia, 
corticobasilar degeneration, and progressive supranuclear 
palsy must also be considered.2,3 sCJD has even presented 
as a stroke.5
Considering rapidly progressive dementia, myoclonus, 
akinesia, mutism, positive CSF 14-3-3 protein and RT-QulC, 
MRI high-intensity signal abnormalities in the caudate nu-
cleus on DWI and routine investigations that do not indicate 
an alternative diagnosis, the diagnosis of the patient is CJD, 
most probably the sporadic type.8
F I G U R E  2  EEG showing periodic synchronized electric discharges on multiple EEGs refractory to seizure medication
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This patient case was remarkable in his progressive dementia 
given its uniquely significant rapidity over 6 weeks. Typically, 
onset of symptoms from presentation to a hospital ranges from 
2  months to 2  years.3-4,6,7 This patient's progression was so 
rapid that he became irreversibly comatose significantly prior 
to the turnaround time of CSF prion analysis. Furthermore, his 
F I G U R E  3  Proposed diagnostic pathway for the workup of a patient with rapidly progressive cognitive decline. NMDAR, N-methyl-D-
aspartate receptor; VGKC, voltage-gated potassium channel (Source: https://thejns.org/focus /view/journ als/neuro surgf ocus/39/5/artic le-pE2.xml or 
https://doi.org/10.3171/2015.8.FOCUS 15328)
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CSF yielded no such protein when he was 2 weeks into his rapid 
deterioration. These discrepancies confounded the initial diag-
nosis. This case is also remarkable that the patient is still alive 
at the 3-year point. sCJD has been documented to run a faster 
course than vCJD yet our patient does not have vCJD given 
no pulvinar sign and lack of psychiatric manifestations domi-
nating the course of disease. Previous literature notes a patient 
with sCJD who had survived for 2 and a half years.9 Although 
the gold standard for diagnosis is tissue pathological confirma-
tion, but brain biopsy was not performed at the early stages of 
diagnosis due to failure of securing neurosurgical service and 
facility, which is not uncommon at the community hospital set-
tings. Later in the diagnosis process when CSF markers became 
positive, indication for brain biopsy was not justified consider-
ing risk-benefit assessment, low sensitivity, and no change in 
treatment regardless of the result (Figure 3).10 Our patient is 
surviving beyond 3 years currently. He continues to remain un-
usual in his rapidity, development, and longevity.
4 |  CONCLUSIONS
Physicians should be aware that for a patient presenting with 
rapidly progressive dementia, Creutzfeldt-Jakob Disease 
(CJD) should be included as one of the differential diagnoses. 
Since CJD can present with various forms of symptoms, and 
although a rare disease, it should not be ruled out by negative 
laboratory results and images. The gold standard diagnosis is 
confirmation by brain biopsy, but due to restrictions for oper-
ating room sterilizations, low sensitivity, high morbidity, and 
the fact that the positive result does not change the treatment 
in most cases, brain biopsy is not routinely done. It is very 
important to rule out treatable diseases in differential diagno-
sis such as meningitis, meningoencephalitis, CNS vasculitis, 
hypothyroidism, sarcoidosis, toxicities, paraneoplastic syn-
dromes, and primary neoplasms. Our case depicts a case CJD 
in a fully functional patient who declined to a comatose state 
in 6 weeks. Although negative on initial workup, CSF 14-
3-3 protein, and RT-QulC became positive well over 6 weeks 
into his illness. This initial progression is unusually rapid. 
However, as of this article's submission date, the patient is 
still alive at a subacute facility 3 years after diagnosis. Both 
the rapid deterioration and protracted survival are atypical.
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